TY - JOUR
T1 - Signal 3 availability limits the CD8 T cell response to a solid tumor
AU - Curtsinger, Julie M.
AU - Gerner, Michael Y.
AU - Lins, Debra C.
AU - Mescher, Matthew F.
N1 - Copyright:
Copyright 2017 Elsevier B.V., All rights reserved.
PY - 2007/6/1
Y1 - 2007/6/1
N2 - CD8 T cells need a third signal, along with Ag and costimulation, for effective survival and development of effector functions, and this can be provided by IL-12 or type I IFN. Adoptively transferred OT-I T cells, specific for H-2Kb and OVA, encounter Ag in the draining lymph nodes of mice with the OVA-espressing E.G7 tumor growing at a s.c. site. The OT-I cells respond by undergoing limited clonal expansion and development of effector functions (granzyme B expression and IFN-γ production), and they migrate to the tumor where they persist but fail to control tumor growth. In contrast, OT-I T cells deficient for both the IL-12 and type I IFN receptors expand only transiently and rapidly disappear. These results suggested that some signal 3 cytokine is available, but that it is insufficient to support a CTL response that can control tumor growth. Consistent with this, administration of IL-12 at day 10 of tumor growth resulted in a large and sustained expansion of wild-type OT-I cells with enhanced effector functions, and tumor growth was controlled. This did not occur when the OT-I cells lacked the IL-12 and type I IFN receptors, demonstrating that the therapeutic effect of IL-12 results from direct delivery of signal 3 to the CD8 T cells responding to tumor Ag in the signal 3-deficient environment of the tumor.
AB - CD8 T cells need a third signal, along with Ag and costimulation, for effective survival and development of effector functions, and this can be provided by IL-12 or type I IFN. Adoptively transferred OT-I T cells, specific for H-2Kb and OVA, encounter Ag in the draining lymph nodes of mice with the OVA-espressing E.G7 tumor growing at a s.c. site. The OT-I cells respond by undergoing limited clonal expansion and development of effector functions (granzyme B expression and IFN-γ production), and they migrate to the tumor where they persist but fail to control tumor growth. In contrast, OT-I T cells deficient for both the IL-12 and type I IFN receptors expand only transiently and rapidly disappear. These results suggested that some signal 3 cytokine is available, but that it is insufficient to support a CTL response that can control tumor growth. Consistent with this, administration of IL-12 at day 10 of tumor growth resulted in a large and sustained expansion of wild-type OT-I cells with enhanced effector functions, and tumor growth was controlled. This did not occur when the OT-I cells lacked the IL-12 and type I IFN receptors, demonstrating that the therapeutic effect of IL-12 results from direct delivery of signal 3 to the CD8 T cells responding to tumor Ag in the signal 3-deficient environment of the tumor.
UR - http://www.scopus.com/inward/record.url?scp=34249780834&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34249780834&partnerID=8YFLogxK
U2 - 10.4049/jimmunol.178.11.6752
DO - 10.4049/jimmunol.178.11.6752
M3 - Article
C2 - 17513722
AN - SCOPUS:34249780834
SN - 0022-1767
VL - 178
SP - 6752
EP - 6760
JO - Journal of Immunology
JF - Journal of Immunology
IS - 11
ER -